Comparing the fixed combination dorzolamide-timolol (CosoptR) to concomitant administration of 2% dorzolamide (TrusoptR) and 0.5% timolol - a randomized controlled trial and a replacement study

Abstract

The results of the randomized trial indicate that the fixed combination dorzolamide-timolol (Cosopt) was as effective as its components in controlling IOP, confirming results seen in phase 3 clinical trials. However, in the replacement study, utilization of the combination drug offered a statistically significant additional IOP reduction (P < 0.0001), which duplicates results from previous replacement studies.